Fudan University
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- Private
- Established
- 1905-01-01
- Employees
- 1K
- Market Cap
- -
- Website
- http://www.fudan.edu.cn
Artificial Intelligence Assisted Breast Ultrasound in Breast Cancer Screening
Not Applicable
Completed
- Conditions
- Interventions
- First Posted Date
- 2024-07-26
- Last Posted Date
- 2024-07-26
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 21790
- Registration Number
- NCT06521788
- Locations
- 🇨🇳
Maternal and Infant Healthy Centre of Hongkou District, Shanghai, Shanghai, Shanghai, China
🇨🇳Shanghai Pudong New Area Healthcare Hospital For Women & Children, Shanghai, China
🇨🇳Fudan University Shanghai Cancer Center, Shanghai, China
Exploratory Clinical Study of SHR-0302 and SHR-2554 in Patients With Relapsed/Refractory Peripheral T Cell Lymphoma
Phase 2
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-07-25
- Last Posted Date
- 2024-08-21
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 25
- Registration Number
- NCT06519526
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, China
An Open-label, Single-arm Study of JWCAR201 in the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma
- First Posted Date
- 2024-07-24
- Last Posted Date
- 2024-07-24
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 9
- Registration Number
- NCT06517004
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, China
Neoadjuvant Treatment of gBRCA-Mutated HER2-Negative Breast Cancer With HRS-1167 and Famitinib ± Camrelizumab
Phase 2
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-07-23
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 130
- Registration Number
- NCT06516289
- Locations
- 🇨🇳
Breast cancer institute of Fudan University Cancer Hospital, Shanghai, Shanghai, China
A Prospective Study of MSS-type Metastatic Colorectal Cancer Receiving Multiple Lines of Standard Chemotherapy, Bevacizumab Combined With Adebrelimab
Phase 2
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-07-22
- Last Posted Date
- 2024-07-22
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 100
- Registration Number
- NCT06513221
Real-world Study on the Management of Hematological Toxicities Associated With Targeted Therapies for Breast Cancer
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-07-16
- Last Posted Date
- 2024-07-31
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 1000
- Registration Number
- NCT06503380
- Locations
- 🇨🇳
Zhi-Ming Shao, Shanghai, Not US/Canada, China
Cranial Radiotherapy Plus Chemoimmunotherapy in Untreated Driver-mutation Negative NSCLC With Stable Brain Metastasis
Phase 2
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-07-15
- Last Posted Date
- 2024-08-28
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 54
- Registration Number
- NCT06501391
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, China
Cranial Radiotherapy Plus Chemoimmunotherapy in Untreated Driver-mutation Negative NSCLC With Active Brain Metastasis
Phase 2
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-07-15
- Last Posted Date
- 2024-08-28
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 40
- Registration Number
- NCT06501378
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, China
Effectiveness of Gut Microbiota-targeted Diatery Intervention Among People Living With HIV
Not Applicable
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-07-12
- Last Posted Date
- 2024-07-12
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 110
- Registration Number
- NCT06498401
Predicting Response to Chemotherapy in Colorectal Cancer Via Multi-dimensional Analyses of the Tumor Associated Neutrophils
- First Posted Date
- 2024-07-11
- Last Posted Date
- 2024-07-11
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 653
- Registration Number
- NCT06495827
© Copyright 2024. All Rights Reserved by MedPath